论文部分内容阅读
目的观察大剂量阿托伐他汀治疗对急性冠脉综合征(ACS)合并糖尿病患者的近期疗效。方法将100例ACS合并糖尿病患者随机均分为阿托伐他汀10mg/d组(A组)和阿托伐他汀40mg/d组(B组),采用流式细胞术检测外周血NF-κB活性,酶联免疫吸附法和乳胶增强投射免疫比浊法分别检测IL-6和高敏C反应蛋白(hsCRP)水平,统计两组治疗期间心血管事件发生率。结果两组治疗后,外周血NF-κB活性以及IL-6、hsCRP水平均低于治疗前(P<0.05或P<0.01),B组低于A组(P<0.05或P<0.01)。B组近期心血管事件发生率低于A组(10%vs.18%)(P<0.05)。结论大剂量阿托伐他汀能明显抑制ACS合并糖尿病患者体内炎性反应,减少近期心血管事件的发生。
Objective To observe the short-term effect of high-dose atorvastatin on patients with acute coronary syndrome (ACS) complicated with diabetes mellitus. Methods 100 patients with ACS complicated with diabetes were randomly divided into atorvastatin 10mg / d group (A group) and atorvastatin 40mg / d group (group B). The activity of NF-κB in peripheral blood was detected by flow cytometry , The level of IL-6 and high sensitive C-reactive protein (hsCRP) were detected by enzyme-linked immunosorbent assay (ELISA) and latex-enhanced immunoturbidimetry, and the incidence of cardiovascular events was calculated. Results After treatment, the levels of NF-κB and hsCRP in peripheral blood were lower than those before treatment (P <0.05 or P <0.01), and those in group B were lower than those in group A (P <0.05 or P <0.01). The recent incidence of cardiovascular events in group B was lower than in group A (10% vs. 18%) (P <0.05). Conclusions High-dose atorvastatin can significantly inhibit the inflammatory reaction in ACS patients with diabetes mellitus and reduce the occurrence of recent cardiovascular events.